SG11201907391SA - Novel vegfr-2 targeting immunotherapy approach - Google Patents
Novel vegfr-2 targeting immunotherapy approachInfo
- Publication number
- SG11201907391SA SG11201907391SA SG11201907391SA SG11201907391SA SG11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA SG 11201907391S A SG11201907391S A SG 11201907391SA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- cwwg
- receptor protein
- international
- vegf receptor
- Prior art date
Links
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title abstract 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 7
- 201000011510 cancer Diseases 0.000 abstract 7
- 108091008605 VEGF receptors Proteins 0.000 abstract 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 6
- 108020004414 DNA Proteins 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 3
- 241000607142 Salmonella Species 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 238000002619 cancer immunotherapy Methods 0.000 abstract 3
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 101100095119 Rattus norvegicus Scfd1 gene Proteins 0.000 abstract 1
- 206010038389 Renal cancer Diseases 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000002458 carcinoid tumor Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 201000010982 kidney cancer Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/423—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17156718 | 2017-02-17 | ||
| PCT/EP2018/053918 WO2018149982A1 (en) | 2017-02-17 | 2018-02-16 | Novel vegfr-2 targeting immunotherapy approach |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907391SA true SG11201907391SA (en) | 2019-09-27 |
Family
ID=58094260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907391SA SG11201907391SA (en) | 2017-02-17 | 2018-02-16 | Novel vegfr-2 targeting immunotherapy approach |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10980868B2 (enExample) |
| EP (1) | EP3583200A1 (enExample) |
| JP (2) | JP7712060B2 (enExample) |
| KR (2) | KR20240170928A (enExample) |
| CN (1) | CN110291187A (enExample) |
| AU (1) | AU2018222777B9 (enExample) |
| BR (1) | BR112019016925A2 (enExample) |
| CA (1) | CA3050833A1 (enExample) |
| IL (1) | IL268186A (enExample) |
| MX (1) | MX2019009724A (enExample) |
| RU (1) | RU2019125436A (enExample) |
| SG (1) | SG11201907391SA (enExample) |
| WO (1) | WO2018149982A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250024816A (ko) * | 2015-06-18 | 2025-02-19 | 백심 아게 | 병용 요법을 위한 vegfr-2 표적화 dna 백신 |
| KR20210058825A (ko) * | 2018-09-05 | 2021-05-24 | 백심 아게 | 병용 요법용 신생항원 표적화 dna 백신 |
| EP4090321A1 (en) * | 2020-01-13 | 2022-11-23 | Vaximm AG | Salmonella-based dna vaccines in combination with an antibiotic |
| CN113527509B (zh) * | 2020-04-17 | 2023-09-26 | 深圳华大生命科学研究院 | 含有重组蛋白和保护蛋白的复合物在治疗肺鳞癌中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| LT2794849T (lt) | 2011-12-22 | 2017-12-11 | Vaximm Ag | Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas |
| DK2869836T3 (da) * | 2012-07-05 | 2019-11-25 | Vaximm Ag | Dna-vaccine til anvendelse hos patienter med pankreascancer |
| EP2988762B1 (en) * | 2013-04-25 | 2018-06-06 | Vaximm AG | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| DK3082850T3 (da) * | 2013-12-18 | 2019-10-07 | Vaximm Gmbh | Msln-targeteret dna-vaccine til cancerimmunterapi |
| WO2015142875A1 (en) | 2014-03-17 | 2015-09-24 | The Trustees Of The University Of Pennsylvania | Compositions and methods using modified salmonella |
| KR20250024816A (ko) * | 2015-06-18 | 2025-02-19 | 백심 아게 | 병용 요법을 위한 vegfr-2 표적화 dna 백신 |
| KR20190027834A (ko) | 2016-07-13 | 2019-03-15 | 백심 아게 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
-
2018
- 2018-02-16 JP JP2019544614A patent/JP7712060B2/ja active Active
- 2018-02-16 CA CA3050833A patent/CA3050833A1/en active Pending
- 2018-02-16 AU AU2018222777A patent/AU2018222777B9/en active Active
- 2018-02-16 EP EP18704568.7A patent/EP3583200A1/en active Pending
- 2018-02-16 BR BR112019016925-3A patent/BR112019016925A2/pt not_active Application Discontinuation
- 2018-02-16 MX MX2019009724A patent/MX2019009724A/es unknown
- 2018-02-16 US US16/486,425 patent/US10980868B2/en active Active
- 2018-02-16 RU RU2019125436A patent/RU2019125436A/ru not_active Application Discontinuation
- 2018-02-16 CN CN201880012318.8A patent/CN110291187A/zh active Pending
- 2018-02-16 KR KR1020247035606A patent/KR20240170928A/ko active Pending
- 2018-02-16 SG SG11201907391SA patent/SG11201907391SA/en unknown
- 2018-02-16 KR KR1020197026398A patent/KR20190117603A/ko not_active Ceased
- 2018-02-16 WO PCT/EP2018/053918 patent/WO2018149982A1/en not_active Ceased
-
2019
- 2019-07-21 IL IL268186A patent/IL268186A/en unknown
-
2023
- 2023-08-18 JP JP2023133276A patent/JP2023160838A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190117603A (ko) | 2019-10-16 |
| AU2018222777B9 (en) | 2024-02-22 |
| KR20240170928A (ko) | 2024-12-05 |
| WO2018149982A1 (en) | 2018-08-23 |
| JP2020507332A (ja) | 2020-03-12 |
| RU2019125436A (ru) | 2021-03-17 |
| JP7712060B2 (ja) | 2025-07-23 |
| BR112019016925A2 (pt) | 2020-05-26 |
| JP2023160838A (ja) | 2023-11-02 |
| MX2019009724A (es) | 2019-10-07 |
| EP3583200A1 (en) | 2019-12-25 |
| AU2018222777B2 (en) | 2024-02-01 |
| US10980868B2 (en) | 2021-04-20 |
| AU2018222777A1 (en) | 2019-08-08 |
| US20200038496A1 (en) | 2020-02-06 |
| CA3050833A1 (en) | 2018-08-23 |
| CN110291187A (zh) | 2019-09-27 |
| IL268186A (en) | 2019-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201407972RA (en) | High-affinity monoclonal antibodies to glypican-3 and use thereof | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407508RA (en) | Encoding and decoding based on blending of sequences of samples along time | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201806992VA (en) | Antibodies to tigit | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201808176TA (en) | Gene therapy for treating mucopolysaccharidosis type ii | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof |